Evidence map›Paper›PMID 29357974›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2018

[Research Progress in the Therapeutic Strategy Based on Targeting at 
Lung Cancer Stem Cell].

Hongjin Lai, Feng Lin, Nan Chen, Shu Wen, Xiao Hu, Lunxu Liu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hongjin LaiWest China School Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Feng LinDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Nan ChenWest China School Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Shu WenDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Xiao HuDepartment of Thoracic Surgery, the Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China.
Lunxu LiuDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Sichuan University · CNWest China Hospital of Sichuan University · CNAffiliated Hospital of Guizhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With high morbidity and mortality, lung cancer is a major threat to human health and one of the focuses of tumor researches. Lung cancer stem cells (LCSCs) are regarded as a subpopulation of cells within lung cancer tissues with the capacity of self-renewal and differentiation, and might be related to tumorigenesis and heterogeneity of lung cancer. Tumor recurrence, metastasis and drug resistance of lung cancers could be clarified by LCSC hypothesis. Thus it's therapeutically prospective to target at these cells. This review summarizes the biomarkers of LCSCs and their aberrant signal pathways, as well as the therapeutic strategies targeting at LCSCs.

Indexed as

AnimalsHumansLung NeoplasmsMolecular Targeted TherapyNeoplastic Stem CellsSignal TransductionLung cancer stem cellsLung neoplasmsMolecular targeted therapyNeoplastic stem cells

Identifiers

PMID29357974
PMCPMC5972359
OpenAlexW2795076378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.